Immunomodulatory drugs (IMiDs) are a class of drugs including the likes of thalidomide, which are used in the treatment of cancers such as multiple myeloma (MM). In this interview, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Benjamin Barwick, MD, of Emory University, Atlanta, GA, discusses the talks given at the meeting which discussed IMiDs, and how resistance to them in MM can be driven by various enhancers and transcription factors that lead to worse outcomes for patients.
Genetic elements driving IMiD resistance in multiple myeloma
